The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective

PIROLA, CARLOS JOSE; SOOKOIAN, SILVIA

Clinical and Molecular Hepatology

Korean Association for the Study of the Liver

Lugar: Seul; Año: 2024 vol. 30 p. 174 - 176

2287-2728

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its severe clinical form, metabolic dysfunction-associated steatohepatitis (MASH), are chronic liver diseases that are becoming increasingly prevalent. Accurate identification of the stages of MASH is crucial for patient treatment, as it is associated with an increased risk of cirrhosis, liver failure, liver cancer, and mortality as it progresses. The understanding of disease pathogenesis has advanced significantly in the past decade, largely due to the use of OMICS and high-throughput technologies. Genomics has enabled the identification of genetic variants that confer either risk or protection against steatotic liver diseases and fibrosis. Epigenetics/epigenomics has helped to clarify the relationship between MASLD and comorbidities, disease severity, and even the interaction with the microbiome, as recently described. Besides, liver transcriptomics have revealed the key mechanisms regulating gene expression in the context of MASLD and MASH. Despite significant progress in comprehending the molecular structure of MASLD and MASH, a substantial gap remains between the insights gained from OMICs research and their practical application in clinical settings.